Fran ois Nader, M.D., 69 Director since: 2019 Term expires: 2028 2025 Attendance: 100% Committees Compensation & Talent (Chair) Nominating & Corporate Governance (Chair) Education French doctorate in Medicine from St. Joseph University in Lebanon Physician Executive M.B.A. from the University of Tennessee Why this director is valuable to Moderna Dr. Nader brings decades of experience in the healthcare industry to the Board, having served as an executive for organizations at various stages of development, including as a public pharmaceutical company CEO. Dr. Nader helps guide our strategy through his insights into various stages of vaccine development across our portfolio, including clinical development, engagement with regulators, and commercialization. His experience on the boards of public and private healthcare companies from small cap to large cap across the globe help inform and guide our growth as we scale our organization. Other Public Boards Tectonic Therapeutic, Inc. (since February 2026), Chair BenevolentAI (2021-2024), Chair Talaris Therapeutics, Inc. (2018-2023), Chair Acceleron Pharma Inc. (2014-2021), Chair Alexion Pharmaceuticals, Inc. (2017-2021) Prevail Therapeutics Inc. (2018-2021), Chair Dr. Nader served as President, CEO and Executive Director of NPS Pharmaceuticals from 2008 until 2015, when the company was acquired. During his tenure as CEO, Dr. Nader transformed NPS Pharma into a leading global biotechnology company focused on delivering innovative therapies to patients with rare diseases. From September 2023 to January 2024, Dr. Nader served as the acting Chief Executive Officer of BenevolentAI while the company conducted a CEO search. Prior to NPS, Dr. Nader was a venture partner at Care Capital. He previously served on Aventis Pharma s North America Leadership Team, holding a number of executive positions in integrated healthcare markets and medical and regulatory affairs. Dr. Nader previously led global commercial operations at the Pasteur Vaccines division of Rhone-Poulenc. He previously served as a senior advisor for Blackstone Life Sciences. Dr. Nader is the former Chairman of BioNJ, New Jersey s biotechnology trade organization, and previously served on the board of the Biotechnology Industry Organization.